Ionis Pharmaceuticals Inc (IONS) Gets a Buy Rating from Needham

Needham analyst Chad Messer reiterated a Buy rating on Ionis Pharmaceuticals Inc (IONSResearch Report) today and set a price target of $87.00. The company’s shares closed last Monday at $59.80.

According to TipRanks.com, Messer is a 4-star analyst with an average return of 4.9% and a 40.2% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals Inc, Autolus Therapeutics Plc, and Akcea Therapeutics Inc.

Ionis Pharmaceuticals Inc has an analyst consensus of Hold, with a price target consensus of $64.67.

See today’s analyst top recommended stocks >>

The company has a one-year high of $86.58 and a one-year low of $43.27. Currently, Ionis Pharmaceuticals Inc has an average volume of 1.02M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs.